PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer (NCT07190469)
A Phase 1, Open-label, Multicenter Clinical Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics and Anti-Cancer Activity of PQ203 in Patients With Advanced Solid Tumor Malignancies
🩺 Plain-English Summary (8th-Grade Level)
The primary purposes of this study are to determine the safety and tolerability of PQ203 in patients with advanced solid tumors including triple negative breast cancer (TNBC), and to determine a recommended Phase 2 dose level for future studies in TNBC.
Who can join: Review the eligibility criteria below.
Location: MD Anderson Cancer Center — Houston, Texas
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (4 Sites)
- MD Anderson Cancer Center — Houston, Texas
- NEXT Oncology — San Antonio, Texas
- START Mountain Region — West Valley City, Utah
- Princess Margaret Cancer Centre — Toronto, Ontario
📞 Contact the Study Coordinator
Phone: (713) 745-7813
Email: DDufner@mdanderson.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Triple Negative Breast Cancer (TNBC)
- OCTANE: Adjuvant Liposomal Doxorubicin and Carboplatin for Early-stage Triple-negative Breast Cancer — Elizabeth, New Jersey
- A Phase II Study of Biomarker-Guided De-escalation Using Anthracycline-Free Neoadjuvant Chemoimmunotherapy in Early-Stage Triple Negative Breast Cancer (TNBC) Patients With High Tumor-Infiltrating Lymphocytes (TILs) — Syracuse, New York
- Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer — Grand Rapids, Michigan
- A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer — Boston, Massachusetts
Explore by condition: All Triple Negative Breast Cancer (TNBC) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.